Clinical Trials Sponsored by Chiesi Farmaceutici S.p.A.

Total 301 results

Chiesi Farmaceutici S.p.A.

Completed

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD) | COPD

United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration (LISPAP)

Respiratory Distress Syndrome (RDS)

United States
Chiesi Farmaceutici S.p.A.

Available

Expanded Access to Velmanase Alfa

Alpha-Mannosidosis
Chiesi Farmaceutici S.p.A.

Completed

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (TRIFORCE)

Chronic Obstructive Pulmonary Disease

Germany
Chiesi Farmaceutici S.p.A.

Completed

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

Asthma; Eosinophilic

Bulgaria
Chiesi Farmaceutici S.p.A.

Terminated

A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)

Neonatal Respiratory Distress Syndrome

Italy
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (GLY2)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Chiesi Farmaceutici S.p.A.

Completed

Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate

Pulmonary Disease, Chronic Obstructive

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4)

COPD

Poland
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients (Trigon)

Chronic Obstructive Pulmonary Disease

Bulgaria, Germany, Poland, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence (ADVICE)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (TRIMARAN)

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

Asthma

Bulgaria, Germany, Italy, Netherlands, Poland
Chiesi Farmaceutici S.p.A.

Completed

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

COPD (Chronic Obstructive Pulmonary Disease)

China, Korea, Republic of, Taiwan
Chiesi Farmaceutici S.p.A.

Completed

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Germany
Chiesi Farmaceutici S.p.A.

Withdrawn

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (SHAMAN)

Alpha-Mannosidosis
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study (Curpap)

Respiratory Distress Syndrome, Newborn

Italy, Spain, Czechia, France, Portugal
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (PAED4)

Asthma in Children

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients

Organ or Tissue Transplant; Complications

France
Chiesi Farmaceutici S.p.A.

Completed

Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD (GlycoNEXT)

Chronic Obstructive Pulmonary Disease (COPD)

Czechia, Germany, Hungary, Romania
Chiesi Farmaceutici S.p.A.

Completed

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD (PIONEER)

Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A.

Completed

A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (CT03 Core)

Cystic Fibrosis

Spain, Ukraine, Czechia, France, Germany, Hungary, Poland, Russian Federation
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old

Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

Italy
Chiesi Farmaceutici S.p.A.

Completed

Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (FAIR)

Chronic Obstructive Pulmonary Disease

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (FORTE)

Asthma

Ukraine, Bulgaria, Italy
Chiesi Farmaceutici S.p.A.

Completed

beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study (CLEAR)

Acute Rhinosinusitis

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children (PAED2/FRESH)

Asthma

Spain, France, Romania, Bulgaria, Germany, Hungary, Italy, Poland, Russian Federation, Slovakia, Ukraine
Chiesi Farmaceutici S.p.A.

Completed

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Childhood Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Poland
Chiesi Farmaceutici S.p.A.

Recruiting

PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) (TRIBE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Chiesi Farmaceutici S.p.A.

Recruiting

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

COPD | COPD Exacerbation

United States, Bulgaria, Hungary, Poland, Argentina, Czechia, Mexico, Canada, Puerto Rico, Romania
Chiesi Farmaceutici S.p.A.

Active, not recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF

Idiopathic Pulmonary Fibrosis

North Macedonia, Ukraine, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Study in Adult Patients With Moderate to Severe Asthma (FEEL)

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (MiSTIC)

Asthma

Hungary

3

Subscribe